BTC comments
This article was originally published in The Tan Sheet
Executive Summary
FDA clarifies the comment period regarding behind-the-counter availability of some nonprescription drugs continues through Dec. 17, the agency says in a Nov. 27 Federal Register notice. The docket for comments on the topic will remain open for 30 days following the meeting FDA conducted Nov. 14 to obtain comments on BTC availability, but in its Oct. 4 notice announcing the meeting, the agency incorrectly listed the deadline as Nov. 28....
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.